All 30 patients with the hardest-to-treat variant were cured.
For millions living with chronic hepatitis C — a virus that quietly dismantles the liver over decades — the search for a reliable cure has long been shadowed by the stubborn resistance of certain viral strains. A real-world study from Wenzhou, China, now offers a rare moment of clarity: a two-drug combination, colbopasvir and sofosbuvir, cured 112 of 113 patients across multiple difficult-to-treat variants, including genotype 3b, which has historically defied standard therapies. The findings arrive not from a controlled trial but from clinical practice, lending them a particular weight in the ongoing global effort to eliminate hepatitis C as a public health threat.
- Hepatitis C's most resistant strains — especially genotype 3b — have long undermined treatment confidence, leaving patients with cirrhosis and co-infections in a precarious gap between illness and cure.
- A 99.1% cure rate across 113 real-world patients, including those with diabetes, hypertension, liver cancer, and hepatitis B co-infection, signals that this combination may close that gap more reliably than existing alternatives.
- Genotype 3b, previously cured at only 76% with competing therapies, achieved 100% clearance here — a result that could reshape treatment protocols for one of the hardest-to-reach patient populations.
- Beyond eliminating the virus, the drugs measurably reversed liver scarring and improved organ function over twelve weeks, suggesting the body's capacity to heal when the assault finally stops.
- The study's retrospective design, small co-infection subgroups, and absence of decompensated cirrhosis patients leave meaningful questions open — larger, prospective trials remain the necessary next step.
In Wenzhou, China, a research team reviewed the outcomes of 113 patients with chronic hepatitis C who had taken a daily combination of colbopasvir and sofosbuvir for twelve weeks. When viral clearance was assessed a full year after treatment ended, 112 of those patients were cured — a sustained virologic response rate of 99.1 percent.
The results were especially striking across hepatitis C's more resistant genetic variants. All 30 patients with genotype 3b achieved clearance — a meaningful contrast to the roughly 76 percent cure rate seen with alternative therapies for that subtype. Genotypes 3a and 6a also reached 100% response rates, as did the 17 patients with compensated cirrhosis. Among genotype 1b patients, 14 of 15 were cured; the single non-responder also carried a hepatitis B co-infection. Patients with diabetes, hypertension, and even hepatocellular carcinoma were all cured, and no serious adverse events were recorded throughout the study.
The treatment's effects extended beyond viral elimination. Liver function scores and fibrosis markers — measures of the scarring hepatitis C inflicts over years — improved significantly from the start of treatment through the year-long follow-up. The liver, it appeared, was not merely cleared of infection but actively recovering.
This carries real weight in China, where chronic hepatitis C is a leading driver of cirrhosis and liver cancer, silently progressing in patients until intervention becomes far more complicated. A therapy effective across diverse subtypes and in patients with existing liver damage meaningfully widens the window for treatment.
The researchers are candid about the study's boundaries: its retrospective design, the small size of co-infection subgroups, and the exclusion of patients with decompensated cirrhosis all limit how far the conclusions can stretch. Longer follow-up and larger prospective trials are still needed. But a 99.1 percent cure rate, achieved in ordinary clinical conditions across a genuinely varied patient population, marks colbopasvir-sofosbuvir as a serious instrument in the effort to reduce hepatitis C's burden.
A team of researchers in Wenzhou, China, tracked 113 patients with chronic hepatitis C who received a combination of two antiviral drugs—colbopasvir and sofosbuvir—taken daily for twelve weeks. When they checked for viral clearance a year after treatment ended, the results were striking: 112 of the 113 patients had achieved what doctors call sustained virologic response, a cure rate of 99.1 percent.
The strength of these findings becomes clearer when you look at the breakdown by viral subtype. Hepatitis C comes in several genetic variants, and some are notoriously difficult to treat. Genotype 3b, in particular, has historically resisted standard therapies. In this study, all 30 patients with genotype 3b were cured. The same held true for the 35 patients with genotype 3a and the 23 with genotype 6a—perfect success rates across the board. Among the 15 patients with genotype 1b, 14 were cured, yielding a 93.3 percent response. Even the 17 patients with compensated cirrhosis, a scarred liver that still functions, all achieved viral clearance.
The one patient who did not respond had both genotype 1b infection and hepatitis B co-infection, a combination that proved resistant. Among the nine other patients with both viruses, nine were cured. The study also included patients with other complications: ten with hypertension, nineteen with diabetes, one with hepatocellular carcinoma. All were cured. The researchers noted no serious adverse events and no patients who had to stop treatment because of side effects. The most common complaints were mild—headache, nausea, fatigue.
Beyond viral clearance, the drugs improved the physical state of the liver itself. Doctors measured liver function using the ALBI score and assessed fibrosis, the scarring that hepatitis C causes, using two different scoring systems. All three measures showed significant improvement from the start of treatment through the end of the twelve-week course and again at the year-long follow-up checkpoint. The liver was not just clearing the virus; it was healing.
This matters because chronic hepatitis C remains a leading cause of cirrhosis and liver cancer in China. The virus silently damages the organ over years or decades, and once advanced scarring sets in, treatment becomes riskier and outcomes less certain. A therapy that works reliably across different viral subtypes and in patients with existing liver damage—including those with cirrhosis—expands the window for intervention. The colbopasvir-sofosbuvir combination, which China has approved, appears to offer that breadth.
The researchers acknowledge the limits of their work. The study was retrospective, meaning they reviewed medical records rather than following patients forward in real time. The groups with hepatitis B or HIV co-infection were small. They did not include patients with decompensated cirrhosis, the most severe form where the liver has begun to fail. And they did not track patients beyond one year. Still, the 99.1 percent cure rate, achieved in a real-world setting across a diverse group of patients, suggests a tool that could meaningfully reduce the burden of hepatitis C in the region and beyond.
Citas Notables
Colbopasvir plus sofosbuvir is highly effective and safe for chronic hepatitis C in Eastern China, including genotype 3b and patients with compensated cirrhosis or HBV co-infection.— Study authors
La Conversación del Hearth Otra perspectiva de la historia
Why does genotype 3b matter so much? It sounds like a technical detail.
Because it's the genotype that has historically beaten other drugs. When you have a therapy that works on 3b at 100 percent, you're solving a problem that's been hard to solve. It changes who can be treated.
And the patients with cirrhosis—that's the scarred liver. Why treat them at all if the damage is already done?
Because the scarring can stop progressing once the virus is gone. The liver can stabilize, sometimes even improve. You're not reversing the damage, but you're preventing it from getting worse. That's the difference between a life of complications and a life that's manageable.
One person failed. What made them different?
They had both genotype 1b and hepatitis B. It's the only combination that didn't respond. Everyone else with either condition alone was cured. That one overlap is the outlier.
Is 99.1 percent cure rate unusual?
For a real-world study—not a controlled trial, but actual patients in clinics—it's exceptional. You're not in a lab. These are people with other illnesses, taking other medications, with varying degrees of liver damage. To get that close to perfect is rare.
What happens next?
Larger studies, especially in patients with more advanced cirrhosis. And longer follow-up to make sure the cure holds. But the signal is clear enough that this becomes a standard option for treatment programs.